The focus of this article is to better understand the impact on Antares Pharma (NASDAQ:ATRS) of the dispute between Antares and privately-held Medac Pharma over patents regarding subcutaneous formulations of methotrexate and the impending PDUFA date for approval of Medac's competing product, Rasuvo.
As background, Antares Pharma focuses on developing and commercializing self-administered subcutaneous pharmaceutical products based on three principal technology platforms: (1) Vision reusable needle-free injectors; (2) Vibex disposable pressure-assisted auto-injectors; and (3) disposable multi-use pen injectors. ATRS has four approved products. TevTropin, Gelnique and Elestrin are products sold by partners with ATRS receiving royalty or licensing income. Otrexup, a subcutaneous formulation of methotrexate for the treatment of arthritis and psoriasis, is the first proprietary product that...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|